<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04710173</url>
  </required_header>
  <id_info>
    <org_study_id>fdpicu-07</org_study_id>
    <nct_id>NCT04710173</nct_id>
  </id_info>
  <brief_title>Establishment of a Early Risk Model of ECMO in Children With ARDS</brief_title>
  <official_title>Establishment of a Early Risk Model of Extracorporeal Membrane Oxygenation（ECMO） in Children With Acute Respiratory Distress Syndrome （ARDS） in China</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Children's Hospital of Fudan University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>The Children's Hospital of Zhejiang University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Children's Hospital of Chongqing Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Guangdong Provincial People's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Chinese PLA General Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Children's Hospital of Fudan University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The key problem in the treatment of ARDS is refractory hypoxemia. Extracorporeal Membrane&#xD;
      Oxygenation (ECMO) is an extracorporeal oxygenation of venous blood to eliminate carbon&#xD;
      dioxide and return to the body. It has been an important part of the rescue treatment for&#xD;
      ARDS. This study intends to explore the timing of ECMO. The main research hypothesis is that&#xD;
      the appropriate timing of ECMO treatment can improve the weaning success rate and survival&#xD;
      rate of children with severe ARDS; it is expected to provide a basis for determining the best&#xD;
      timing of ECMO treatment&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Severe acute respiratory distress syndrome (ARDS), especially those caused by severe viral&#xD;
      pneumonia, is still an important factor in the death of children, with a case fatality rate&#xD;
      of 55%. The treatment includes lung protective ventilation and advanced ventilation support,&#xD;
      but the effect is still not ideal for severe patients. ECMO can effectively support the&#xD;
      respiratory system and provide good oxygen exchange. However, the survival rate of ECMO&#xD;
      treatment in children with ARDS has a large bias.One of the key factors is the uneven timing&#xD;
      of ECMO activation, which significantly affects the prognosis.This study intends to design a&#xD;
      multi-center, prospective, non-randomized controlled trial , through retrospective research&#xD;
      to find relevant factors affecting the prognosis of ECMO treatment, and to screen key&#xD;
      indicators related to the timing of intervention; through a prospective cohort study to&#xD;
      screen Good indicators and cut-off values suitable for starting ECMO , constructing and&#xD;
      verifying comprehensive prediction models.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 1, 2021</start_date>
  <completion_date type="Anticipated">September 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">September 30, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Survival rate</measure>
    <time_frame>28 days after hospital discharge</time_frame>
    <description>The survival rate of children in 28 days after hospital discharge</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>ECMO weaning rate</measure>
    <time_frame>48 hours after ECMO weaning</time_frame>
    <description>The success of ECMO weaning is defined as the survival of patients after ECMO weaning for 48 hours</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">150</enrollment>
  <condition>ARDS</condition>
  <arm_group>
    <arm_group_label>ARDS children</arm_group_label>
    <description>children with severe ARDS</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>ECMO</intervention_name>
    <description>VV-ECMO</description>
    <arm_group_label>ARDS children</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      2 ml whole blood in EDTA tube&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        children with acute respiratory distress syndrome（ARDS） admitted to the pediatric intensive&#xD;
        care unit（PICU） of all the study centers&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Acute onset; within 7 days of clinical insult&#xD;
&#xD;
          -  Chest imaging (radiograph or computed tomography) findings of new infiltrates&#xD;
             (unilateral or bilateral) consistent with acute parenchymal disease&#xD;
&#xD;
          -  Edema not fully explained by fluid overload or cardiac failure&#xD;
&#xD;
          -  May present as new acute lung disease in setting of chronic lung disease and/or heart&#xD;
             disease&#xD;
&#xD;
          -  OI≥16&#xD;
&#xD;
          -  Viral etiology is clear&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Perinatal lung disease&#xD;
&#xD;
          -  Large intracranial bleed with mass effect or need for neurosurgical intervention&#xD;
&#xD;
          -  Hypoxic cardiac arrest without adequate CPR&#xD;
&#xD;
          -  Irreversible underlying cardiac or lung pathology (and not a transplant candidate)&#xD;
&#xD;
          -  Pulmonary hypertension and chronic lung disease&#xD;
&#xD;
          -  Chronic multiorgan dysfunction&#xD;
&#xD;
          -  Incurable malignancy&#xD;
&#xD;
          -  Allogenic bone marrow recipients with pulmonary infiltrates&#xD;
&#xD;
          -  Hepatic or renal failure&#xD;
&#xD;
          -  Pertussis infection in infants&#xD;
&#xD;
          -  Fungal pneumonia&#xD;
&#xD;
          -  Immunodeficiency&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ye Cheng, doctor</last_name>
    <role>Study Director</role>
    <affiliation>Children's Hospital of Fudan University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ye Cheng, doctor</last_name>
    <phone>13816566641</phone>
    <email>chengyemonkey@163.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jiayun Ying, doctor</last_name>
    <phone>18817583962</phone>
    <email>jiayundoctor@163.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Chinese PLA General Hospital</name>
      <address>
        <city>Beijing</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>xiaoyang hong</last_name>
      <phone>13311057633</phone>
      <email>jyhongxy@163.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Chongqing Medical University</name>
      <address>
        <city>Chongqing</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>yingfu chen</last_name>
      <phone>17723175548</phone>
      <email>chenyfpicu@163.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Guangdong Provincial People's Hospital</name>
      <address>
        <city>Guanzhou</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>yuwei guo</last_name>
      <phone>13423661583</phone>
      <email>2003kellylaw@163.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>January 12, 2021</study_first_submitted>
  <study_first_submitted_qc>January 12, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">January 14, 2021</study_first_posted>
  <last_update_submitted>August 2, 2021</last_update_submitted>
  <last_update_submitted_qc>August 2, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>ECMO</keyword>
  <keyword>ARDS</keyword>
  <keyword>pediatric</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

